The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT01058005




Registration number
NCT01058005
Ethics application status
Date submitted
26/01/2010
Date registered
28/01/2010
Date last updated
3/09/2014

Titles & IDs
Public title
Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis
Scientific title
A Multicenter, Randomized, Open-Label, Parallel-Group, Active-Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon Beta-1a) to Natalizumab in Subjects With Relapsing Remitting Multiple Sclerosis
Secondary ID [1] 0 0
101MS325
Universal Trial Number (UTN)
Trial acronym
SURPASS
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Relapsing Remitting Multiple Sclerosis 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - BG00002 (natalizumab)
Treatment: Drugs - interferon beta-1a
Treatment: Drugs - glatiramer acetate

Experimental: Natalizumab -

Active Comparator: Interferon Beta-1a -

Active Comparator: Glatiramer Acetate -


Treatment: Drugs: BG00002 (natalizumab)
300 mg intravenous injection every 4 weeks

Treatment: Drugs: interferon beta-1a
44 mcg subcutaneous injection 3 times per week

Treatment: Drugs: glatiramer acetate
20 mg subcutaneous injection once daily

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Incidence of Treatment-emergent Serious Adverse Events (SAEs) - An SAE was defined as any untoward medical occurrence that at any dose: results in death; in the view of the Investigator, places the subject at immediate risk of death (a life-threatening event; however, this does not include an event that, had it occurred in a more severe form, might have caused death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; or results in a congenital anomaly/birth defect. An SAE may also have been any other medically important event that, in the opinion of the Investigator, may jeopardize the subject or may require intervention to prevent one of the other outcomes listed in the definition above. See Adverse Events section below for further details.
Timepoint [1] 0 0
up to 108 Weeks

Eligibility
Key inclusion criteria
Key

1. Have a diagnosis of relapsing remitting multiple sclerosis (MS) as defined by the
revised McDonald Committee criteria (Polman 2005).

2. Must have been treated with a stable regimen of either glatiramer acetate (20 mg per
day subcutaneous) or interferon beta-1a (44 mcg 3 times per week subcutaneous) as
their principal first therapy for MS for 6 to 18 months prior to randomization. (Note:
prior treatment with another MS therapy of = 30 days total duration is not
exclusionary [e.g. titration to 44 mcg is allowed]).

3. Have had disease activity within 12 months prior to screening while on therapy;
disease activity must be observed after a minimum of 6 months on therapy. Qualifying
disease activity is defined as:

- One or more clinical relapses OR

- Two or more new MRI lesions (gadolinium [Gd+] and/or T2 hyperintense) For
inclusion purposes: (a) a relapse is defined as neurologic signs and/or symptoms
documented in the medical record by a neurologist and of sufficient duration to
be determined by the Investigator or the Treating Physician as consistent with an
MS relapse or (b) MRI activity must be verified by the central reader center.

4. Be naïve to natalizumab.

5. Have a documented Expanded Disability Status Scale (EDSS) score between 0.0 and 5.5,
inclusive.

Key
Minimum age
18 Years
Maximum age
60 Years
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Have a diagnosis of primary progressive, secondary progressive, or progressive
relapsing MS (as defined by Lublin and Reingold, 1996). These conditions require the
presence of continuous clinical disease worsening over a period of at least 3 months.
Patients with these conditions may also have superimposed relapses, but are
distinguished from relapsing-remitting patients by the lack of clinically stable
periods or clinical improvement.

2. Have known intolerance, contraindication to, or history of non-compliance with, the
use of glatiramer acetate or interferon beta-1a.

3. Have had an MS exacerbation (relapse) within 30 days prior to randomization AND/OR the
patient has not stabilized from a previous relapse, in the opinion of the
Investigator, prior to randomization.

4. The patient is considered by the Investigator to be immunocompromised based on medical
history, physical examination, laboratory testing, or due to prior immunosuppressive
or immunomodulating treatment.

5. Subjects for whom MRI is contraindicated, i.e., have pacemakers or other
contraindicated implanted metal devices, have suffered or are at risk for side effects
from gadolinium (Gd), or have claustrophobia that cannot be medically managed.

6. History of any clinically significant (as determined by the Investigator) cardiac,
endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary,
neurologic, dermatologic, psychiatric, renal, or other major disease that would
preclude participation in a clinical trial.

7. History of malignant disease, including solid tumors and hematologic malignancies
(with the exception of basal cell and squamous cell carcinomas of the skin that have
been completely excised and are considered cured).

8. Known history of human immunodeficiency virus (HIV).

9. Positive test result for hepatitis C virus (test for hepatitis C virus antibody
[HCVAb]) or hepatitis B virus (test for hepatitis B surface antigen [HBsAg] and/or
hepatitis B core antibody [HBcAb]).

10. History of transplantation or any anti-rejection therapy.

11. History of progressive multifocal leukoencephalopathy (PML).

NOTE: Other protocol-defined inclusion/exclusion criteria may apply.

Study design
Purpose of the study
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Terminated
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Research Site - Fitzroy
Recruitment postcode(s) [1] 0 0
- Fitzroy
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Kentucky
Country [7] 0 0
United States of America
State/province [7] 0 0
Louisiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Michigan
Country [9] 0 0
United States of America
State/province [9] 0 0
New York
Country [10] 0 0
United States of America
State/province [10] 0 0
North Carolina
Country [11] 0 0
United States of America
State/province [11] 0 0
Ohio
Country [12] 0 0
United States of America
State/province [12] 0 0
Tennessee
Country [13] 0 0
United States of America
State/province [13] 0 0
Texas
Country [14] 0 0
United States of America
State/province [14] 0 0
Virginia
Country [15] 0 0
United States of America
State/province [15] 0 0
Washington
Country [16] 0 0
United States of America
State/province [16] 0 0
West Virginia
Country [17] 0 0
Canada
State/province [17] 0 0
Quebec
Country [18] 0 0
Czech Republic
State/province [18] 0 0
Pardubice
Country [19] 0 0
Finland
State/province [19] 0 0
Tampere
Country [20] 0 0
France
State/province [20] 0 0
Bas-Rhin
Country [21] 0 0
Hungary
State/province [21] 0 0
Komárom-Esztergom
Country [22] 0 0
Hungary
State/province [22] 0 0
Budapest
Country [23] 0 0
Hungary
State/province [23] 0 0
Nyiregyhaza
Country [24] 0 0
Italy
State/province [24] 0 0
Catania
Country [25] 0 0
Italy
State/province [25] 0 0
Napoli
Country [26] 0 0
Italy
State/province [26] 0 0
Rome
Country [27] 0 0
Latvia
State/province [27] 0 0
Riga
Country [28] 0 0
Poland
State/province [28] 0 0
Lodzkie
Country [29] 0 0
Poland
State/province [29] 0 0
Podlaskie
Country [30] 0 0
Poland
State/province [30] 0 0
Pomorskie
Country [31] 0 0
Slovenia
State/province [31] 0 0
Ljubljana
Country [32] 0 0
Spain
State/province [32] 0 0
Alicante
Country [33] 0 0
Spain
State/province [33] 0 0
Barcelona
Country [34] 0 0
Spain
State/province [34] 0 0
Girona
Country [35] 0 0
Spain
State/province [35] 0 0
Madrid
Country [36] 0 0
Spain
State/province [36] 0 0
Santa Cruz de Tenerife
Country [37] 0 0
Spain
State/province [37] 0 0
Sevilla
Country [38] 0 0
Sweden
State/province [38] 0 0
Molndal

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Biogen
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Elan Pharmaceuticals
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This was a multicenter, randomized, open-label, parallel-group, active-controlled study.
Prior to randomization, participants were to have been treated with glatiramer acetate or
interferon ß-1a (44 µg). Participants were to be randomized to receive natalizumab,
interferon ß-1a 44 µg, or glatiramer acetate.
Trial website
https://clinicaltrials.gov/show/NCT01058005
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Medical Director
Address 0 0
Biogen
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
For IPD and results data, please see https://clinicaltrials.gov/show/NCT01058005